Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Cancer research and PI3K/AKT/mTOR pathway, with related work in Fulvestrant, Breast cancer, Cytotoxic T cell. Notable publications include 'Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer', 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers', and 'Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors'.
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
<scp>PAK1</scp> mediates pancreatic cancer cell migration and resistance to <scp>MET</scp> inhibition
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics
Multimodal Microvascular Imaging Reveals that Selective Inhibition of Class I PI3K Is Sufficient to Induce an Antivascular Response
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal